{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Authenticated Consensus Deep research connector; completed provider output retained privately; original-source access checked separately",
  "queries": [
    "https://consensus.app/search/for-an-exhaustive-primary-literature-review-suppor/VpbkCn0iRIG1gtRae9Cv0w/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 10,
  "primary_comparisons": [
    {
      "pmid": "33567185",
      "doi": "10.1056/NEJMoa2032183",
      "source_type": "primary study report",
      "study_group": "STEP1-NCT03548935",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Standard-dose efficacy versus exact microdose scope",
      "result_comparison": "Consensus separates the 2.4 mg STEP 1 trial from strict below-0.5 mg maintenance. The examined original confirms 1,961 adults, BMI-defined enrollment, 68 weeks and 14.9% versus 2.4% mean loss. Its 86.4% versus 31.5% at least-5% responder result belongs to 2.4 mg, not the titration step.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33567185/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-8-16-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "26358288",
      "doi": "10.2337/dc15-0165",
      "source_type": "primary study report",
      "study_group": "WEEKLY-SEMA-PHASE2-12W",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Short weekly dose-finding does not establish long maintenance",
      "result_comparison": "Consensus identifies the early weekly phase 2 trial as 12-week boundary evidence. The examined original abstract confirms weekly 0.1-0.8 mg without escalation, higher escalated arms and phase 3 selection of 0.5/1 mg. Low-arm body tables were inaccessible in our public route; we did not promote provider snippets to a full-body audit or a 24-68-week result.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/26358288/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-21-29-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "30122305",
      "doi": "10.1016/S0140-6736(18)31773-2",
      "source_type": "primary study report",
      "study_group": "PMID30122305",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Daily low milligrams cannot be converted to weekly equivalence",
      "result_comparison": "Consensus labels the obesity dose-ranging original as a daily schedule. The examined Methods-containing abstract explicitly says every active dose was once daily. Its 52-week positive weight results therefore do not establish sub-0.5 mg once-weekly maintenance, and no arithmetic dose conversion was used.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/30122305/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "38826889",
      "doi": "10.7759/cureus.59558",
      "source_type": "primary study report",
      "study_group": "PMID38826889",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Lower-than-obesity-dose is not the registered microdose",
      "result_comparison": "Consensus notes this chart review maintained 1 mg or 2 mg. The examined original confirms six-month maintenance in 16 and nine cases respectively, with only 25 completers from 40 patients. Observed losses at these doses and selected completion do not establish the strict microdose or randomized equivalence.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38826889/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-8-16-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "41421448",
      "doi": "10.1016/j.clnesp.2025.102885",
      "source_type": "primary study report",
      "study_group": "PMID41421448",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Mixed-dose PCOS combination and horizon",
      "result_comparison": "Consensus describes a six-month 0.25-0.5 mg plus-metformin pilot with fat loss and no lean-mass loss. The original reports the weight contrast after five months, combines metformin with pooled semaglutide doses and finds a nonsignificant lean-mass contrast. We retain these distinctions: no isolated below-0.5 mg causal estimate, no registered 24-week weight endpoint and no positive muscle-function protection result.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41421448/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-53-60-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "42217114",
      "doi": "10.1007/s12325-026-03636-x",
      "source_type": "primary study report",
      "study_group": "PMID42217114",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Food-noise recall survey versus necessary mediation",
      "result_comparison": "Consensus characterizes INFORM as retrospective and recall-based. Our selected original Methods and Results independently confirm self-report, no statistical testing, 550 survey participants but 547 complete FNQ responses, and 39% currently using 2.4 mg. The lower recollected-to-current scores do not establish necessary mediation or low-dose efficacy.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42217114/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-16-22-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\42217114-s2-p1-3-4-5-11-13.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\42217114-s3-p0-1-4.json"
      ]
    },
    {
      "pmid": "41068996",
      "doi": "10.1111/dom.70141",
      "source_type": "primary study report",
      "study_group": "PMID41068996",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Lean mass and grip strength are different outcomes",
      "result_comparison": "Consensus distinguishes SEMALEAN from older-adult retrospective decline. The original SEMALEAN abstract reports 106 completers, initial 3 kg lean-mass loss followed by stabilization and a 4.5 kg grip increase at 12 months during 2.4 mg treatment. Its uncontrolled design supports the distinction between mass and function, not microdose muscle protection.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41068996/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-45-53-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40631351",
      "doi": "10.2147/DDDT.S531778",
      "source_type": "primary study report",
      "study_group": "PMID40631351",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Conflicting older-diabetes function evidence",
      "result_comparison": "Consensus identifies the older-adult retrospective cohort as a contrary functional boundary. The original abstract associates exposure with mass and function decline over 24 months but does not establish random allocation or remove nutrition/comorbidity confounding. Neither this finding nor SEMALEAN proves all doses harmful or protective.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40631351/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-45-53-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "41725422",
      "doi": "10.1111/dom.70538",
      "source_type": "primary study report",
      "study_group": "PMID41725422",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Supplemental original-body correction beyond provider coverage",
      "result_comparison": "FLEX-SEMA was not a cited anchor in the observed Consensus report; our separate original-source retrieval filled this gap. Selected Results show that 5.4% remained on 0.25 mg at three months, while six-month dose maintenance was driven mainly by satisfactory prior results. Body cumulative responder thresholds are 84.4%, 64.6%, 35.4% and 9.4%; the indexed abstract instead mislabels nonoverlapping bin percentages as cumulative. We use the body distinction and do not interpret a final-dose null as noninferiority.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41725422/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\41725422-s1-p0-1-7-8.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\41725422-s2-p1-3-14-15-16-19.json"
      ]
    },
    {
      "pmid": "42323166",
      "doi": "10.1016/j.ajcnut.2026.101403",
      "source_type": "primary study report",
      "study_group": "NCT05548647",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Additional long-term objective-subjective dissociation",
      "result_comparison": "The observed Consensus report explains the need to separate appetite from food noise but does not cite this 60-week original as an anchor. Our selected Methods/Results add the explicit finding: intake and weight differences persist at weeks 40/60 while hunger and food-preoccupation contrasts no longer reach significance. These were VAS/eating-control measures, not a direct intervention on FNQ necessity.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42323166/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\42323166-s1-p0-1-3-4-8-12.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\body-presentation-receipts\\42323166-s2-p8-10-19-21-22.json"
      ]
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp1-microdosing\\consensus-provider-checkpoint-1551-private.json",
      "sha256": "402867bbf545618b0aecfd197a70c62fa8e5bbee6ceb136d31064c52c32f9d7f"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T16:38:31.999413+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}